T-cell regulation of CNS autoimmune disease.

The immune system’s own brakes are failing in multiple sclerosis, and this project aims to figure out exactly how two key molecules—CTLA-4 and IL-10—put those brakes back on. Multiple sclerosis (MS) is a chronic autoimmune disease where the body’s immune cells attack the protective coating around nerves in the brain and spinal cord. Current treatments dampen the entire immune system, leaving patients vulnerable to infections. This research targets a gap: we know that certain regulatory T cells (Tregs) can control the attack, but the molecular switches that turn these cells on and off remain poorly understood. The team has already shown that two distinct types of Tregs—one marked by the protein FoxP3, one without it—can suppress disease in mouse models of MS. They now want to dissect how CTLA-4 shapes the immune system’s T cell repertoire in the thymus and how IL-10-producing cells emerge from inflammatory Th1 cells. This is fundamental science. If successful, it will provide a molecular roadmap for designing therapies that selectively strengthen the body’s own regulatory cells, rather than bludgeoning the entire immune response. That could eventually lead to more precise treatments for MS and other autoimmune conditions, with fewer side effects.